Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Peter Siostrzonek et al.|The Lancet|2017Cited by 1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesPierluigi Tricoci, Kenneth W. Mahaffey, Zhen Huang et al.|New England Journal of Medicine|2011Cited by 753
Clonal Hematopoiesis and Risk of New-Onset Myocarditis and PericarditisArt Schuermans, Michael C. Honigberg, Spencer Flynn et al.|JAMA Cardiology|2025Cited by 14